Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,728 across all filing types
Latest filing 2014-04-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
七届十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the convening and voting results of the company's 18th board meeting of the 7th session, including approval of an external investment and related party transaction proposal and the proposal to convene an extraordinary general meeting. The document is short (661 characters) and primarily announces board decisions rather than providing detailed management or financial information. It is not an annual or interim report, nor a call transcript or earnings release. It fits the category of Board/Management Information (MANG) as it relates to board resolutions and decisions.
2014-04-24 Chinese
七届十次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed by the Supervisory Board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the approval of an external investment and related party transaction plan, including voting results and supervisory opinions. The document is short (743 characters) and serves as a public notice of a board decision rather than a detailed financial report or presentation. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the board resolution. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2014-04-24 Chinese
召开2014年第一次临时股东大会的会议通知
AGM Information Classification · 95% confidence The document is a notice for a shareholders' meeting, specifically the 2014 first extraordinary general meeting (临时股东大会) of Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting time, location, agenda, attendance instructions, and proxy authorization form. There is no financial data, earnings, or report content. It is a meeting notice rather than a report or voting result announcement. Therefore, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2014-04-24 Chinese
七届十七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 7th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It includes details about voting results on various proposals such as a restricted stock incentive plan, stock repurchase, cash performance rewards, and financing plans. The document is clearly about board decisions and voting outcomes rather than a full report or financial statement. It is not an annual or interim report, audit report, or earnings release. It is not a proxy solicitation or AGM material. The key focus is on board meeting resolutions and decisions, which fits the category of Board/Management Information (MANG). The document length is short and contains specific board meeting content, not just an announcement of a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2014-04-22 Chinese
股权激励计划当期购买股份开始公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the commencement of share repurchase under a restricted stock incentive plan. It details the purpose, basis, method, price, quantity, funding source, and expected impact of the share repurchase. The document is an official announcement about the company's share repurchase activity related to an employee incentive plan, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the share repurchase plan and its execution. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back its own shares.
2014-04-22 Chinese
限制性股票激励计划2013年度股权激励基金提取说明的专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is a special attestation report by an accounting firm regarding the 2013 annual stock incentive fund extraction explanation of Kunming Pharmaceutical Group Co., Ltd. It includes an auditor's opinion and detailed financial performance metrics related to the stock incentive plan. The document is a standalone audit-related attestation report focusing on the application of accounting and auditing standards to a specific financial matter (the stock incentive fund extraction). It is not a full annual report, earnings release, or management discussion, but a specific audit verification report. The document length is under 5,000 characters, but it contains substantive audit opinion and financial data related to the stock incentive plan, so it is not merely an announcement. Therefore, it fits best under Audit Report / Information (AR).
2014-04-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.